Immatics Biotechnologies
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
Delivering the Power of T cells to Cancer Patients
Get to know Immatics Biotechnologies
Headquartered in: Tübingen, Germany
Founded in: 2000
Sector: Biotechnology, Medical, Therapeutics
Investor: Private Investor Network, Industrial Tech Fund